MARKET

AVRO

AVRO

AVROBIO
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.91
+0.69
+3.41%
Closed 16:00 06/01 EDT
OPEN
20.32
PREV CLOSE
20.22
HIGH
21.42
LOW
20.00
VOLUME
449.75K
TURNOVER
--
52 WEEK HIGH
29.32
52 WEEK LOW
9.76
MARKET CAP
753.50M
P/E (TTM)
-7.6861
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AVRO stock price target is 36.78 with a high estimate of 58.00 and a low estimate of 13.00.

EPS

AVRO News

More
96 Biggest Movers From Yesterday
Gainers Mmtec, Inc. (NASDAQ: MTC) shares climbed 86.4% to close at $2.05 on Tuesday after reporting its financial results for the year ended December 31, 2019. Revenues jumped 647% to $200,797, in 2019.
Benzinga · 6d ago
61 Stocks Moving In Tuesday's Mid-Day Session
Gainers Mmtec, Inc. (NASDAQ: MTC) shares jumped 98.2% to $2.18 in pre-market trading after reporting its financial results for the year ended December 31, 2019. Revenues jumped 647% to $200,797, in 2019.
Benzinga · 6d ago
AVROBIO (AVRO) Presents At American Society of Gene & Cell Therapy Meeting - Slideshow
Seeking Alpha - Article · 05/14 18:34
AVROBIO Presents New Preclinical Data on Lentiviral Gene Therapy Program for Pompe Disease at ASGCT 2020
Business Wire · 05/14 12:00
AVROBIO Highlights Presentation Of New Preclinical Data On Lentiviral Gene Therapy Program For Pompe Disease At ASGCT
AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced new preclinical data for AVR-RD-03 for Pompe disease showcasing
Benzinga · 05/14 11:01
Avrobio rallies on gene therapy data in Fabry
Seeking Alpha - Article · 05/13 13:16
AVROBIO Reports Updated Clinical Data from Investigational Gene Therapy Programs for Fabry Disease and Cystinosis
Business Wire · 05/13 12:00
The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12)
Benzinga · 05/13 11:40

Industry

Biotechnology & Medical Research
+0.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About AVRO

AVROBIO, Inc. is a clinical-stage gene therapy company. The Company is focused on developing curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. Its gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its product pipeline includes AVR-RD-01, AVR-RD-02, AVR-RD-03 and AVR-RD-04. The Company is developing AVR-RD-01 for the treatment of Fabry disease. AVR-RD-02 is the Company’s gene therapy for Gaucher disease. AVR-RD-03 is being developed for the treatment of Pompe disease. The Company is developing AVR-RD-04 for the treatment of patients with cystinosis.
More

Webull offers kinds of Avrobio Inc stock information, including NASDAQ:AVRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVRO stock news, and many more online research tools to help you make informed decisions.